FRANKFURT, Nov 7 (Reuters) - Jerini (JI4G.DE: Quote, Profile, Research) has signed an agreement with U.S.-based Kos (KOSP.O: Quote, Profile, Research) to develop and market the German biotech firm’s main drug hope, icatibant, in the United States and Canada.
